Insomnia is a serious worldwide health problem that is often comorbid with anxiety. The purpose of the present study was to evaluate the efficacy of a Chinese formula containingSuan Zao Ren Tang(SZRT) andZhi Zi Chi Tang(ZZCT; SZR-ZZC) for improving sleep quality and anxiety states with four indices of Polysomnography (PSG), the Insomnia Severity Index (ISI), the Pittsburgh Sleep Quality Index (PSQI), and the Self Rating Anxiety Scale (SAS).Methods.A randomized, parallel-controlled trial compared SZR-ZZC to lorazepam tablet in insomniacs with anxiety. Patients were randomized to the SZR-ZZC treatment group () and the lorazepam tablet treatment group ().Results. SZR-ZZC significantly improved scores on all four treatment indices. Compared with lorazepam, treatment with SZR-ZZC resulted in a significant reduction in the ISI (), the PSQI (), and wake after sleep onset (WASO;) scores and improved sleep architecture (–0.003) after a 4-week treatment period. Only one subject in the SZR-ZZC group experienced adverse side effects.Conclusion. Treatment with SZR-ZZC for 4 weeks appears to be a relatively safe and effective complementary therapeutic option when aiming to improve sleep quality and anxiety in insomniacs with anxiety.
1 January 2020 in Evidence-Based Complementary and Alternative Medicine
Background. Chronic insomnia is a major public health problem, but there are limited effective therapies. Jiawei Suanzaoren Decoction (JW‐SZRD) has been used as an alternative option for treating insomnia. This study aimed to investigate the long‐term efficacy and safety of JW‐SZRD in combination with lorazepam for chronic insomnia. Methods. A total of 207 participants were analyzed in this study. The treatment group (TG) received JW‐SZRD and lorazepam orally, and the control group (CG) received lorazepam alone. The Insomnia Severity Index (ISI), the Self‐Rating Depression Scale (SDS), the Self‐Rating Anxiety Scale (SAS), and the Somatic Self‐rating Scale (SSS) were evaluated at baseline, weeks 4, 8, and 12. The MOS 36‐item Short Form Health Survey (SF‐36) was assessed at baseline and week 12. Adverse effects (AEs) were evaluated by the Treatment Emergent Symptom Scale (TESS). Results. Both TG and CG showed obvious improvements in the sleep onset latency (SOL) (P = 0.001 and 0.005) and total sleep time (TST) (P = 0.0001 and 0.001). However, TG was more effective than CG at weeks 8 (P = 0.02 for SOL, P = 0.008 for TST) and 12 (P = 0.03 for SOL, P = 0.04 for TST), especially in shortening SOL (Cohen’s d = 1.28). The ISI reduction rate in TG was higher than that in CG at weeks 4, 8, and 12 (P = 0.008, 0.001 and 0.001). After treatment, TG had lower SAS scores (P = 0.0001, 0.007), less somatic symptoms (P < 0.05 or 0.01), higher SF‐36 scores (P < 0.05 or 0.01), better compliance (P = 0.0001), and less adverse effects (P < 0.05 or 0.01) than those in CG. Conclusion. The combination of JW‐SZRD with lorazepam can significantly improve sleep quality with fewer AEs. It is an effective treatment and superior to lorazepam alone for chronic insomnia.